

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton Box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bravecto 1,400 mg spot-on solution for very large dogs (>40 – 56 kg)

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

1,400 mg fluralaner

**3. PACKAGE SIZE**

1 x 5.0 ml  
2 x 5.0 ml

**4. TARGET SPECIES**


Dogs.

**5. INDICATION(S)**

**6. ROUTES OF ADMINISTRATION**

Spot-on use.  
Read the package leaflet before use.

Cap does not come off.



**7. WITHDRAWAL PERIODS**

Not applicable.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Keep the sachet in the outer carton.  
Keep the pipette in the sachet until use.  
Read the package leaflet before use.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Ltd.  
Walton Manor, Walton  
Milton Keynes  
MK7 7AJ

**14. MARKETING AUTHORISATION NUMBER**

Vm 01708/5020

**15. BATCH NUMBER**

Lot {number}

**16. SPECIAL WARNING(S), IF NECESSARY**

Keep the product in the original packaging until use in order to prevent children from getting access to the product. Avoid contact with skin, mouth and/or eye. Do not contact the application site until it is no longer noticeable.  
Wear gloves when handling and administering this product. Read package leaflet for full user safety information.

**17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

POM-V

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Sachet**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bravecto 1,400 mg spot-on solution for very large dogs (>40 – 56 kg)

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

1,400 mg fluralaner


**3. TARGET SPECIES**

Dogs.



**4. ROUTES OF ADMINISTRATION**

For spot-on use



1. Put on gloves. 2. Rotate cap (cap cannot be removed). 3. Apply to skin.

**5. WITHDRAWAL PERIODS**

Not applicable.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

**7. SPECIAL STORAGE PRECAUTIONS**

Keep the sachet in the outer carton.

Keep the pipette in the sachet until use.

**8. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Ltd.  
Walton Manor, Walton  
Milton Keynes  
MK7 7AJ

**9. BATCH NUMBER**

Lot {number}

**10. PACKAGE SIZE**

5.0 ml

**11. INDICATION(S)**

**12. SPECIAL WARNING(S), IF NECESSARY**

**13. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**14. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

For animal treatment only.

**15. MARKETING AUTHORISATION NUMBER**

Vm 01708/5020

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Pipette**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bravecto

**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)**

1,400 mg fluralaner

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

5.0 ml

**6. ROUTE(S) OF ADMINISTRATION**

For spot-on use

**7. WITHDRAWAL PERIOD**

Not applicable

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bravecto 112.5 mg spot-on solution for very small dogs (2 – 4.5 kg)  
Bravecto 250 mg spot-on solution for small dogs (>4.5 – 10 kg)  
Bravecto 500 mg spot-on solution for medium-sized dogs (>10 – 20 kg)  
Bravecto 1,000 mg spot-on solution for large dogs (>20 – 40 kg)  
Bravecto 1,400 mg spot-on solution for very large dogs (>40 – 56 kg)

### **2. COMPOSITION**

Each ml contains 280 mg fluralaner.  
Each pipette delivers:

<b>Bravecto spot-on solution</b>	<b>Pipette content (ml)</b>	<b>Fluralaner (mg)</b>
for very small dogs 2 – 4.5 kg	0.4	112.5
for small dogs >4.5 – 10 kg	0.89	250
for medium-sized dogs >10 – 20 kg	1.79	500
for large dogs >20 – 40 kg	3.57	1,000
for very large dogs >40 – 56 kg	5.0	1,400

Clear colourless to yellow solution.

### **3. TARGET SPECIES**

Dogs.

### **4. INDICATIONS FOR USE**

For the treatment of tick and flea infestations in dogs.

This veterinary medicinal product is a systemic insecticide and acaricide that provides:

- immediate and persistent flea (*Ctenocephalides felis* and *C. canis*) killing activity for 12 weeks,
- immediate and persistent tick (*Ixodes ricinus*, *Rhipicephalus sanguineus* and *Dermacentor reticulatus*) killing activity for 12 weeks.

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For the treatment of demodicosis caused by *Demodex canis*.

For the treatment of sarcoptic mange (*Sarcoptes scabiei* var. *canis*) infestation.

## 5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

## 6. SPECIAL WARNING(S)

### Special warnings:

Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.

Unnecessary use of antiparasitics or use deviating from the instructions given may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each individual animal.

The possibility that other animals in the same household can be a source of re-infection with parasites should be considered, and these should be treated as necessary with an appropriate product.

### Special precautions for safe use in the target species:

Care should be taken to avoid contact with the eyes of the animal. Do not use directly on skin lesions.

Do not wash or allow the dog to become immersed in water or swim in water courses within 3 days after treatment.

In the absence of available data, this veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.

The product should not be administered at intervals shorter than 8 weeks as the safety at shorter intervals has not been tested.

This product is for topical use and should not be administered orally.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Contact with the product should be avoided and disposable protective gloves obtained with this product at the point of sale must be worn when handling the product for the following reasons:

Hypersensitivity reactions have been reported in a small number of people, which can potentially be serious.

Persons with a hypersensitivity to fluralaner or to any of the excipients should avoid any exposure to the product.

The product binds to skin and may also bind to surfaces after spillage of the product. Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact.

If skin contact does occur, wash the affected area immediately with soap and water. In some cases, soap and water are not sufficient to remove the product spilled on the fingers.

Contact with the product may also occur when handling the treated animal.

Make sure that your animal's application site is no longer noticeable before resuming contact with the site of application. This includes cuddling the animal and sharing a bed with the animal. It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.

If skin reactions occur, consult a physician and show them the product packaging. People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

This product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. A used pipette should immediately be disposed of. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.

The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition. In case of spillage onto, for example table or floor surfaces, remove excess product using paper tissue and clean the area with detergent.

#### Pregnancy, lactation and fertility:

Can be used in breeding, pregnant and lactating dogs.

#### Interaction with other medicinal products and other forms of interaction:

None known.

Fluralaner is highly bound to plasma proteins and might compete with other highly bound active substances such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.

During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for dogs and routinely used veterinary medicinal products were observed.

#### Overdose:

Safety was demonstrated in puppies aged 8 – 9 weeks and weighing 2.0 – 3.7 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).

Safety was demonstrated in breeding, pregnant and lactating animals treated with overdoses of up to 3 times the maximum recommended dose.

This veterinary medicinal product was well tolerated in collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 3 times the maximum recommended dose.

#### Major incompatibilities:

None known.

## 7. ADVERSE EVENTS

Dogs:

Common (1 to 10 animals / 100 animals treated):	Skin reactions at the application site (Erythema, Alopecia)**
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Lethargy**, Anorexia** Emesis**

\* observed in clinical trials

\*\* reported during post marketing safety experience, self-limiting and of short duration

# mild and transient

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For spot-on use.

The veterinary medicinal product should be administered in accordance with the following table (corresponding to a dose of 25 - 56 mg fluralaner/kg body weight):

Body weight of dog (kg)	Strength and number of pipettes to be administered				
	Bravecto 112.5 mg	Bravecto 250 mg	Bravecto 500 mg	Bravecto 1,000 mg	Bravecto 1,400 mg
2 - 4.5	1				
>4.5 - 10		1			
>10 - 20			1		
>20 - 40				1	
>40 - 56					1


For dogs above 56 kg body weight, use a combination of two pipettes that most closely matches the body weight.

Underdosing could result in ineffective use and may favour resistance development.

## 9. ADVICE ON CORRECT ADMINISTRATION


### Method of administration

**Step 1:** Immediately before use, open the sachet and remove the pipette. Put on gloves. The pipette should be held by the base or by the upper rigid portion below the cap in an upright position (tip up) for opening it. The twist-and-use cap should be rotated clockwise or counter clockwise one full turn. The cap will stay on the pipette; it is not possible to remove it. The pipette is open and ready for application when the breaking of the seal is felt.



**Step 2:** The dog should be standing or lying with its back horizontal during application. Place the pipette tip vertically against the skin between the shoulder blades of the dog.

**Step 3:** Squeeze the pipette gently and apply the entire contents directly to the dog's skin in one (when volume is small) or several spots along the dog's dorsal line from the shoulder to the base of the tail. Avoid the application of more than 1 ml of solution at any one spot as it could cause some of the solution to run or drip off the dog.



### Treatment schedule

For optimal control of tick and flea infestation, the product should be administered at intervals of 12 weeks.

For the treatment of *Demodex canis* mite infestations, a single dose of the product should be applied. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

For the treatment of sarcoptic mange infestations (*Sarcoptes scabiei* var. *canis*), a single dose of the product should be applied. The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian.

## 10. WITHDRAWAL PERIOD(S)

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.

The pipettes should be kept in the outer packaging to prevent solvent loss or moisture uptake.

The sachets should only be opened immediately prior to use.

Do not use this veterinary medicinal product after the expiry date stated on the packaging after Exp. The expiry date refers to the last day of that month.

## **12. SPECIAL PRECAUTIONS FOR DISPOSAL**

Medicines should not be disposed of via wastewater.

The veterinary medicinal product should not enter water courses as fluralaner may be dangerous for aquatic invertebrates.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

Joint labelling with central marketing authorisations will only include the following wording:

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 01708/5018	112.5 mg
Vm 01708/5023	250 mg
Vm 01708/5026	500 mg
Vm 01708/5015	1,000 mg
Vm 01708/5020	1,400 mg

Each cardboard box contains 1 or 2 pipettes and a pair of gloves per pipette. Not all pack sizes may be marketed.

## **15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED**

May 2023

Find more product information by searching for the 'Product Information Database' or 'PID' on [www.gov.uk](http://www.gov.uk).

## 16. CONTACT DETAILS

Marketing authorisation holder:

MSD Animal Health UK Ltd.  
Walton Manor, Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

Manufacturer responsible for batch release:

Intervet Productions  
Rue de Lyons  
27460 Igoville  
France

Contact details to report suspected adverse reactions:

MSD Animal Health UK Ltd.  
Tel.: +44 (0)1908 685685

## 17. OTHER INFORMATION

The product contributes towards the control of environmental flea populations in areas to which treated dogs have access.

The onset of efficacy is within 8 hours for fleas (*C. felis*) and 12 hours for ticks (*I. ricinus*).

For animal treatment only.

POM-V To be supplied only on veterinary prescription.

Approved 24 January 2024

